100
Views
1
CrossRef citations to date
0
Altmetric
Articles

Internet marketing in healthcare: The case of generic drugs and the contagion effect

, &
Pages 302-310 | Received 29 May 2018, Accepted 26 Sep 2018, Published online: 08 Jan 2019

References

  • Lim WM, Ting DH. Healthcare marketing: contemporary salient issues and future research directions. Int J Healthc Manag. 2012;5(1):3–11. doi: 10.1179/204797012X13293146890048
  • Memisoglu M. Marketing communications for over-the-counter drugs and non-pharmaceutical products: the professionals’ perspective. Int J Healthc Manag. 2017; doi: 10.1080/20479700.2017.1417075
  • Mohapatra S. Better healthcare at reduced cost through electronic integration of patient care data. Int J Electron Healthc. 2009;5(1):27–54. doi: 10.1504/IJEH.2009.026274
  • Mohapatra S. Using biometrics devices for improving automation in hospital management system. Int J Healthc Delivery Reform Initiatives. 2011;3(2):40–48. doi: 10.4018/jhdri.2011040104
  • Mohapatra S. Using integrated information system for patient benefits: a case study in India. Int J Healthc Manag. 2015;8(4):262–271. doi: 10.1179/2047971915Y.0000000007
  • Mohapatra S, Murarka S. Improving patient care in hospital in India by monitoring influential parameters. Int J Healthc Manag. 2016;9(2):83–101. doi: 10.1080/20479700.2015.1101938
  • Bhangale V. Marketing of healthcare services in India: a study on factors influencing patients’ decision making on choice of a hospital. J Manag Mark Healthc. 2011;4(4):229–233.
  • Mendoza RL. Internet medicine and pharmacies: private choice, public risks, and healthcare business. Int J Healthc Manag. 2014;7(3):185–199. doi: 10.1179/2047971914Y.0000000082
  • FDA. Warning Letters. http://www.fda.gov/Drugs/ Guidance Compliance Regulatory Information /Enforcement Activities by FDA/Warning Letters and Notice of Violation Letters to Pharmaceutical Companies/ucm055773.htm, accessed March 2010; 2010.
  • Jambulingam T, Sharma R. Estimating the value of internet marketing in the US pharmaceutical industry. J Med Mark. 2010;10:332–343. doi: 10.1057/jmm.2010.24
  • Srinivasan R, Lilien GL, Rangaswamy A. Technological opportunism and radical technology adoption: an application to E-business. J Mark. 2002;66(July):47–60. doi: 10.1509/jmkg.66.3.47.18508
  • Grewal R, Comer JM, Mehta R. An investigation into the antecedents of organizational participation in business-to-business electronic markets. J Mark. 2001;65(July):17–33. doi: 10.1509/jmkg.65.3.17.18331
  • Handelman JM, Arnold SJ. The role of marketing actions with a social dimension: appeals to the institutional environment. J Mark. 1999;63(July):33–48. doi: 10.1177/002224299906300303
  • Homburg C, Workman JP, Krohmer H. Marketing’s influence within the firm. J Mark. 1999;63(April):1–17. doi: 10.1177/002224299906300201
  • Scott WR. Institutions and organizations. Thousand Oaks (CA): Sage; 1995.
  • Department of Health and Human Services, et al. Guidance for Industry Presenting Risk Information in Prescription Drug and Medical Device Promotion – Draft Guidance, May 2009; 2009.
  • Abedi G, Abedini E. Prioritizing of marketing mix elements effects on patients’ tendency to the hospital using analytic hierarchy process. Int J Healthc Mark. 2017;10(1):34–41. doi: 10.1080/20479700.2016.1231435
  • Fama EF. Efficient capital markets: a review of theory and empirical work. J Finance. 1970;25(5):383–417. doi: 10.2307/2325486
  • Malkiel BG. The efficient market hypothesis and its critics. J Econ Perspect. 2003;17(1):59–82. doi: 10.1257/089533003321164958
  • Scheraga C, Calfee JE. The industry effects of information and regulation in the cigarette markets: 1950–1965. J Public Policy Mark. 1996;15(2):216–226. doi: 10.1177/074391569601500204
  • Davidson WN, Worrell DL. Research notes and communications: The effect of product recall announcements on shareholder wealth. Strategic Manag J. 1992;13:467–473. doi: 10.1002/smj.4250130606
  • Dowdell TD, Govindaraj S, Jain PC. The Tylenol incident, ensuing regulation and stock prices. J Financial Quant Anal. 1992;27:283–301. doi: 10.2307/2331372
  • Dranove D, Olsen C. The economic side effects of dangerous drug announcements. J Law Econ. 1994;37:323–348. doi: 10.1086/467316
  • Ghani WI, Childs NM. Wealth effects of the passage of the nutrition labeling and education Act of 1990 for large U.S. multinational food corporations. J Public Policy Mark. Fall, 1999;18(2):147–158. doi: 10.1177/074391569901800202
  • Sharma A, Lacey N. Linking product development outcomes to market valuation of the firm: The case of the U.S. pharmaceutical industry*. J Product Innovation Manag. 2004;21:297–308. doi: 10.1111/j.0737-6782.2004.00084.x
  • Stigler GJ. The theory of economic regulation. Bell J Econ Manag Sci. spring, 1971;2(1):3–21. doi: 10.2307/3003160
  • Dodd P, Warner JB. On corporate governance. J Financ Econ. 1983;11:401–38. doi: 10.1016/0304-405X(83)90018-1
  • Travlos N. Corporate takeover bids, methods of payment, and bidding firms’ stock returns. J Finance. 1987;42(4):943–62. doi: 10.1111/j.1540-6261.1987.tb03921.x
  • FDA Draft Guidance. Fulfilling Regulatory Requirements for Post Marketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics. January 2014; 2014a.
  • FDA Draft Guidance Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation about Prescription Drugs and Medical Devices, June 2014. January 2014; 2014b.
  • FDA Draft Guidance. Internet/Social Media Platforms with Character Space Limitations – Presenting Risk and Benefits Information for Prescription Drugs and Medical Devices, June 2014; 2014c.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.